Moderna Stock Soars as Personalized Cancer Vaccine Succeeds in Phase 3 Trial With Merck

An experimental personalized cancer vaccine developed by Moderna and Merck delivered encouraging results in its first late-stage clinical trial, pushing both pharmaceutical partners closer to potential regulatory filings. Following the announcement, shares of Moderna vaulted nearly 150% in morning trading, while Merck equity rose more than 10%. As first reported by CNBC Business, the trial provides the first Phase 3 clinical validation for the companies' personalized mRNA oncology treatment.

The Phase 3 study evaluated a cohort of more than 1,100 patients diagnosed with high-risk or advanced melanoma who had previously undergone surgery to remove all detectable cancer. When combined with Keytruda, Merck's established immunotherapy drug, the custom mRNA shot successfully met its primary endpoint by significantly expanding the amount of time patients survived without cancer recurrence compared to Keytruda administered alone. The dual-drug regimen also lowered the risk of cancer metastasizing to distant parts of the body, extending positive Phase 2 trial findings recorded earlier this year.

The substantial disparity in stock movements on Wednesday reflected the existing market capitalization gap between the two healthcare firms prior to the announcement. Heading into the trading session, Merck carried a market value of approximately $333 billion, whereas Moderna was valued at roughly $25 billion. In an interview on CNBC's 'Squawk Box,' Moderna Chief Executive Officer Stéphane Bancel highlighted the clinical breakthrough, describing the trial results as a landmark moment for both medicine and oncology patients.

The late-stage trial will continue running to evaluate secondary outcomes, including long-term overall survival rates. While the joint developers plan to present detailed scientific data at a future global medical conference, a target date for formal submission to U.S. regulatory authorities has not been finalized. Dr. Dean Li, president of Merck Research Laboratories, indicated during a CNBC appearance that formal discussions with health regulators regarding safety data and treatment efficacy are expected to begin within the next few months.

Melanoma represents approximately 1% of all skin cancer diagnoses, yet it accounts for the vast majority of skin cancer deaths globally. Most disease recurrences occur within two to three years following initial treatment and surgical removal. Dr. Jane Healy, head of oncology early development at Merck, noted in an interview that post-surgery patients typically face intense anxiety over potential relapse. She described the clinically meaningful improvement over Keytruda—the current standard of care—as highly encouraging, adding that side effects remained comparable to standard preventative vaccines.

The therapeutic strategy builds on decades of research into individualized medical treatments. Because every patient's tumor possesses a unique set of genetic mutations, the mRNA vaccine is custom-engineered to target specific markers found on an individual's tumor cells. The customized shot trains the human immune system to pinpoint and eliminate those distinct targets, while Keytruda enhances the body's overall capacity to destroy cancer cells. Healy noted that the successful trial offers broader validation for applying personalized mRNA technology across additional cancer types.

Wall Street analysts viewed the late-stage trial outcome as a pivotal catalyst for Moderna's corporate trajectory. In a research note published in June, Leerink Partners analyst Mani Foroohar characterized the Phase 3 data release as a make-or-break juncture for Moderna's stock price. Industry analysts had previously noted that Moderna's market valuation already incorporated expectations that its personalized vaccine platform could succeed across multiple cancer indications. Beyond melanoma, Merck and Moderna are actively testing the mRNA candidate in clinical trials targeting non-small cell lung cancer, renal cell carcinoma, and bladder cancer.